Document is current

Article History

Received: 15 October 2024

Accepted: 31 December 2024

First Online: 6 February 2025

Declarations

:

: Ethical approval has been obtained in France by the research ethics committee Ile-de-France X (ID 2021-A-03194-37), in Spain by the research ethics committees of the Hospital Clinic of Barcelona (ID HCB/2022/0042) and the Sant Joan de Déu Foundation (PS-05-22) and in Denmark by the De Videnskabsetiske Komiteer for Region Hovedstaden (the Scientific Ethics Committees for the Capital Region of Denmark) (ID H-22010899).

: Not applicable.

: Alcediag is an innovative diagnostic company that focuses on mental health, developing and commercializing innovative in vitro diagnostic tests. Alcediag has developed the EDIT-B test, which is based on proprietary RNA editing biomarkers. DW is the CSO of Alcediag. EV has received grants and served as consultant, advisor or CME speaker for the following entities outside the submitted work: AB-Biotics, AbbVie, Adamed, Angelini, Biogen, Beckley-Psytech, Biohaven, Boehringer-Ingelheim, Celon Pharma, Compass, Dainippon Sumitomo Pharma, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo-Smith Kline, HMNC, Idorsia, Johnson & Johnson, Lundbeck, Luye Pharma, Medincell, Merck, Newron, Novartis, Orion Corporation, Organon, Otsuka, Roche, Rovi, Sage, Sanofi-Aventis, Sunovion, Takeda, Teva, and Viatris. AG-P has received CME-related honoraria or consulting fees from Janssen-Cilag, Lundbeck, Casen Recordati, the LCN, Rovi and Angelini, outside the submitted work. JZP has received honoraria from Lundbeck Pharma A/S within the last three years, outside the submitted work. LVK has received honoraria from Lundbeck Pharma and Teva within the last three years, outside the submitted work.